TRAIL mutant membrane penetrating peptide alike-MuR6-TR enhances the antitumor effects of TRAIL in pancreatic carcinoma both in vitro and in vivo
Open Access
- 26 April 2017
- journal article
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 39 (6) , 1468-1476
Abstract
To remedy the drug resistance of natural tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and enhance its antitumor effects, we prepared a type of TRAIL mutant membrane penetrating peptide alike (TMPPA)‑TRAIL mutant R6 (MuR6-TR) by mutating the N‑terminal of the soluble TRAIL gene sequence. The expressed MuR6‑TR protein was purified to treat pancreatic carcinoma cell lines BxPC‑3 and PANC‑1. The inhibitory effects on the proliferation of BxPC‑3 and PANC‑1 cells was assessed with CCK‑8 assay and compared with natural TRAIL. The antitumor effect of MuR6‑TR was assessed on implant tumors derived from PANC‑1 cells in nude mice and compared with gemcitabine. Finally, the soluble MuR6‑TR gene was successfully mutated with 4 amino acids in the N‑terminal of TRAIL and had a molecular size of 513 bp. The mutant MuR6‑TR was connected to pET32a and verified by enzymatic digestion and sequencing. The recombinant MuR6‑TR was transformed and expressed in Escherichia coli. The CCK‑8 assay results indicated that MuR6‑TR inhibited the growth of BxPC‑3 and PANC‑1 cells in a dose‑dependent manner, with IC50 values of 4.63 and 7.84 ng/ml, respectively, which were much lower than that of natural TRAIL. MuR6‑TR demonstrated a higher inhibitory effect on tumor growth (24.2%) than natural TRAIL (14.4%) and an effect similar to that of gemcitabine at an early period. Thus, the mutant MuR6‑TR exhibited a stronger antitumor effect than that of natural TRAIL both in vivo and in vitro and may have potential therapeutic value for pancreatic carcinoma, which requires further validation.Keywords
This publication has 22 references indexed in Scilit:
- Emerging landscape of cell penetrating peptide in reprogramming and gene editingJournal of Controlled Release, 2016
- Recent advances in pancreatic cancer: biology, treatment, and preventionBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2015
- Inhibition of Tumor Growth by Polyarginine-Fused Mutant Cytosine DeaminaseApplied Biochemistry and Biotechnology, 2014
- Synthesis, characterization, and biological activity of poly(arginine)-derived cancer-targeting peptides in HepG2 liver cancer cellsJournal of Peptide Science, 2014
- Targeting apoptosis pathways in pancreatic cancerCancer Letters, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Emerging non‐apoptotic functions of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL)/Apo2LJournal of Cellular Physiology, 2004
- A Unified Model for Apical Caspase ActivationMolecular Cell, 2003
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- Identification and characterization of a new member of the TNF family that induces apoptosisImmunity, 1995